Skip to content
Homepage
Author:
Tango Therapeutics, Inc.
Posted Date:
June 22, 2026
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics, Inc.
June 22, 2026
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
Tango Therapeutics, Inc.
June 9, 2026
Tango Therapeutics Announces Proposed $500 Million Public Offering
Tango Therapeutics, Inc.
June 8, 2026
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
Tango Therapeutics, Inc.
June 8, 2026
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics, Inc.
June 5, 2026
